The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
| 1 Year | 5 Year | 5 Year Annualized | Since IPO | |
|---|---|---|---|---|
| VERA | -42.3% | N/A | N/A | +141% |
| S&P | +13.96% | +91.24% | +13.85% | +64% |
Vera Therapeutics, Inc. is a clinical stage biotechnical company which engages in the development and commercialization of transformative treatments for immunological diseases. The company was founded by Marshall Fordyce in May 2016 and is headquartered in Brisbane, CA.
Vertex Pharmaceuticals' $4.9 billion purchase of Alpine Immune Sciences probably won't be the last acquisition of a company focused on kidney disease.
| Q3 2025 | YOY Change | |
|---|---|---|
| Revenue | $0.00M | 0.0% |
| Gross Profit | -$0.56M | -8.5% |
| Market Cap | $1.85B | -23.5% |
| Market Cap / Employee | $8.28M | 0.0% |
| Employees | 224 | 0.0% |
| Net Income | -$80.29M | -72.2% |
| EBITDA | -$83.37M | -69.2% |
Currently no data to display
Currently no data to display.
Currently no data to display.
| Q3 2025 | YOY Change | |
|---|---|---|
| Net Cash | $57.77M | 112.0% |
| Inventory | 0 | 0.0% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Long Term Debt | $76.74M | 44.7% |
| Short Term Debt | $0.47M | -74.7% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Return On Assets | -56.87% | -7.5% |
| Return On Invested Capital | -64.27% | 61.8% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Free Cash Flow | -$62.04M | -67.1% |
| Operating Free Cash Flow | -$61.91M | -67.8% |
| Metric | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | YoY Change |
|---|---|---|---|---|---|
| Price to Book | 8.05 | 2.65 | 2.81 | 3.96 | -46.40% |
| Price to Tangible Book Value | 8.05 | 2.65 | 2.81 | 3.96 | -46.40% |
| Enterprise Value to EBITDA | -40.72 | -17.55 | -12.86 | -17.22 | -60.13% |
| Return on Equity | -44.8% | -39.5% | -54.8% | -73.2% | 12.49% |
| Total Debt | $54.64M | $54.47M | $77.55M | $77.22M | 40.62% |
No podcast episodes available.
No transcripts available.
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
